Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class, including Saxagliptin (Onglyza), Saxaglitin/Metformin (Kombiglyze XR), Alogliptin (Nesina), Alogliptin/Metformin (Kazano), Alogliptin/Pioglitazone (Oseni), and  Dapagliflozin/Saxagliptin (Qtern).

Stroke victim.

New research, which has been published on  April 14, 2018 in the Journal Pharmacoepidemiology & Drug Safety, entitled “Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: A disproportionality analysis among high‐risk patients” has investigated heart-related side effects reports submitted to the FDA Adverse Event Reporting System (FAERS) from 2006 to 2015.

When concentrating this Postmarketing surveillance on the DPP‐4 class of anti-diabetes medicines, increased reporting of major adverse cardiac events (MACE)] were noted. In particular, signals of disproportional reporting (SDR) emerged for heart failure with drugs containing linagliptin (e.g., Linagliptin (Tradjenta), Linagliptin/Metformin (Jentadueto), Linagliptin/Empagliflozin (Glyxambi)), and saxagliptin (e.g., Saxagliptin (Onglyza), Saxagliptin/Metformin (Kombiglyze XR), and Dapagliflozin/Saxagliptin (Qtern)), for myocardial infarction with drugs containing alogliptin [e.g., Alogliptin (Nesina), Alogliptin/Metformin (Kazano), and Alogliptin/Pioglitazone (Oseni)), and for cerebral infarction with sitagliptin [e.g., Sitagliptin (Januvia), Sitagliptin/Metformin (Janumet), Sitagliptin (Juvisync), and Sitagliptin/Ertugliflozin (Steglujan)).

The collective evidence from these analyses would strongly suggest that drug label warnings about heart failure which were mandated by the FDA for certain DPP-4 diabetes drugs back in 2016 urgently need differential updating and strengthening in order to adequately inform physicians and patients alike about the potentially fatal risks  associated with some DPP-4 class medications.

Thus, a more precise and stronger warning for myocardial infarction (heart attack) would be justified for Alogliptin (Nesina), Alogliptin/Metformin (Kazano), and Alogliptin/Pioglitazone (Oseni)). Likewise, a more precise and stronger warning for cerebral infarction (stroke) would be justified for Sitagliptin (Januvia), Sitagliptin/Metformin (Janumet), Sitagliptin (Juvisync), and Sitagliptin/Ertugliflozin (Steglujan). Hopefully, FDA will act swiftly upon.

Gliptines, inhibitors of dipeptidyl peptidase 4 (DPP-4),  are a class of oral hypoglycemics that block DPP-4. They are be used to treat diabetes mellitus type 2. Glucagon increases blood glucose levels, and DPP-4 inhibitors reduce glucagon and blood glucose levels. The mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.

Print Friendly, PDF & Email

Tags: , , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

@peepso_user_30549(sajibuni)
Hello Everyone out there,I am here to give my testimony about a Herbalist doctor who helped me . I was infected with HERPES SIMPLEX VIRUS five years ago, i went to many hospitals for cure but there was no solution, so I was thinking how can I get a solution out so that my body can be okay. One day I was in the river side thinking where I can go to get solution. so a lady walked to me telling me why am I so sad and i open up all to her telling her my problem, she told me that she can help me out, she introduce me to a doctor who uses herbal medication to cure HERPES SIMPLEX VIRUS and gave me his email, so i mail him. He told me all the things I need to do and also give me instructions to take, which I followed properly. Before I knew what is happening after two weeks the HERPES SIMPLEX VIRUS that was in my body got vanished . so if you are also heart broken and also need a help, you can also email him at dr.chalaherbalhome@gmail.com or Contact him today on whatsapp number… Read more
8 months ago 8 months ago

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Study reveals restoration of retinal and visual function following gene therapy October 19, 2020
    A breakthrough study, led by researchers from the University of California, Irvine, results in the restoration of retinal and visual functions of mice models suffering from inherited retinal disease.
  • Scientists map the human proteome October 19, 2020
    Twenty years after the release of the human genome, the genetic "blueprint" of human life, an international research team, including the University of British Columbia's Chris Overall, has now mapped the first draft sequence of the human proteome.
  • The line of succession in neuron function October 19, 2020
    A specific region of messenger RNAs, the 3' untranslated region (3'UTR), plays an important role for cells to function properly. During embryonic development, 3'UTRs in hundreds of RNAs lengthen exclusively in neurons, which is crucial for the cells of the brain to function properly. The lab of Valérie Hilgers at the Max Planck Institute of […]
  • Pinpointing the 'silent' mutations that gave the coronavirus an evolutionary edge October 16, 2020
    We know that the coronavirus behind the COVID-19 crisis lived harmlessly in bats and other wildlife before it jumped the species barrier and spilled over to humans.
  • Transposons could be rewiring our brains October 16, 2020
    A new study by neuroscientists at the University of Oxford shows that mobile genetic elements that were active in the genomes of our ancestors could be closely linked to important functions in our brain and might help diversify our behavior, cognition and emotions.
  • Asymmetric optical camouflage: Tuneable reflective color accompanied by optical Janus effect October 20, 2020
    Deliverying viewing-direction sensitive information display across single sheet of transreflective window is introduced. Based on the experimental verification of theoretical modelling, scientists in Republic of Korea invented colour tuneable optical device that displays different colours and messages depending on viewing direction which is completely new and exotic optical phenomenon. A step further, they realized asymmetric […]
  • Researchers at the forefront of developing machine learning methods for chemical discovery October 20, 2020
    Prof. Alexandre Tkatchenko and his research team at the University of Luxembourg have been awarded grants totalling 500,000 euros to conduct research in the emerging field of machine learning methods for chemical discoveries.
  • COVID-19: Distancing and masks are not enough October 20, 2020
    Decades-old data is being used to describe the propagation of tiny droplets. Now a fluid dynamics team has developed new models: Masks and distancing are good, but not enough. Even with a mask, infectious droplets can be transmitted over several meters and remain in the air longer than previously thought.
  • Oncotarget: Inhibition of HAS2 and hyaluronic acid production by 1,25-Dihydroxyvitamin D3 in breast October 20, 2020
    Oncotarget Volume 11, Issue 30 reported that genomic profiling of murine mammary tumor cells with differential VDR expression identified 35 transcripts that were altered by the 1,25D3-VDR complex including Hyaluronan Synthase-2.
  • US adults' likelihood of accepting COVID-19 vaccination October 20, 2020
    In this survey study of U.S. adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self- reported willingness to receive vaccination. These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available.
Top